Our Portfolio
A Biotech Venture Capital Fund
We seek technologies that power modern biotech—from next-generation research tools to data and AI automation platforms. The best of these early-stage opportunities often require institutional access and large minimum investments. VC23 enables individuals and family offices to participate in high-impact ventures once reserved for large funds.
Current & Legacy Portfolios
Legacy Portfolio
Bastion Health delivers a telehealth platform focused exclusively on men’s health, combining at-home tests (PSA, urine, semen, hormone, STD/STI screening) with virtual urologist visits and personalized care navigation.
Current VC23 Portfolio
Enrich Biosystems develops advanced cell isolation and enrichment technologies that improve recovery, purity, and viability for single-cell and proteomic applications.
Legacy Portfolio
RevMedica is developing advanced surgical devices, starting with a laparoscopic stapler that combines a reusable power module with a disposable sterile body for efficiency and sustainability.
Current VC23 Portfolio
CellSonic develops non-invasive bioelectric shockwave devices to stimulate cell repair, wound healing, and cancer treatment without drugs or surgery.
Current VC23 Portfolio
Intus Bio develops molecular diagnostic tools and point-of-care platforms to enable rapid, accessible detection of infectious and genetic diseases.
Current VC23 Portfolio
Fluent Bio was acquired by Illumina in 2024 for single-cell technology integration.
Fluent Bio enables high-throughput single-cell RNA sequencing using scalable, instrument-free barcoding.
Current VC23 Portfolio
ProteoWise revolutionizes proteomics with HyperBlot, an automated multiplexed platform delivering rapid, quantitative protein analysis.
Current VC23 Portfolio
Codetta Bio develops integrated multiplexed assays combining DNA, RNA, and protein detection to enable comprehensive, high-throughput molecular diagnostics and precision medicine.
Legacy Portfolio
Encapsulate Bio develops a patient-on-a-chip system that grows mini tumors to test cancer drugs and personalize treatment decisions.
Legacy Portfolio
Twist Bioscience IPO’d in 2018 on Nasdaq under ticker TWST.
Twist Bioscience manufactures synthetic DNA at scale using silicon-based technology, enabling advances in genomics, drug discovery, and data storage.
Legacy Portfolio
Bactana was acquired by Kemin Industries in May of 2025.
They were a Cornell University spinoff at the forefront of anaerobic fermentation and the isolation of postbiotic molecules produced by commensal bacteria in the microbiome.
Legacy Portfolio
10x Genomics IPO’d in 2019 on Nasdaq under ticker TXG.
10x Genomics develops single-cell and spatial biology tools that enable high-resolution molecular profiling for biomedical research and discovery.